Patterns and Predictors of Mortality After Waitlist Dropout of Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation

被引:6
|
作者
Gorgen, Andre [1 ,2 ]
Rosales, Roizar [1 ]
Sadler, Erin [2 ]
Beecroft, Robert [3 ]
Knox, Jennifer [4 ]
Dawson, Laura A. [5 ]
Ghanekar, Anand [1 ,2 ]
Grant, David [1 ,2 ]
Greig, Paul D. [1 ,2 ]
Sapisochin, Gonzalo [1 ,2 ]
机构
[1] Univ Toronto, Univ Hlth Network, Multiorgan Transplant Program, Toronto, ON, Canada
[2] Univ Toronto, Dept Gen Surg, Toronto, ON, Canada
[3] Univ Toronto, Univ Hlth Network, Div Intervent Radiol, Joint Dept Imaging, Toronto, ON, Canada
[4] Univ Toronto, Princess Margaret Canc Ctr, Dept Med Oncol, Toronto, ON, Canada
[5] Univ Toronto, Princess Margaret Canc Ctr, Dept Radiat Oncol, Radiat Med Program, Toronto, ON, Canada
关键词
SURVIVAL; MODEL; RISK; CANDIDATES; DIAGNOSIS; RATES;
D O I
10.1097/TP.0000000000002616
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. There is a lack of information about survival after dropout from the liver transplant waiting list. Therefore, we aimed to assess the overall survival, and risk factors for death, after waiting list dropout due to hepatocellular carcinoma (HCC) progression. Methods. We assessed patients who dropped out of the liver transplant waiting list between 2000 and 2016 in a single, large academic North American center. Patients were divided into 3 groups according to the types of HCC progression: locally advanced disease (LAD), extrahepatic disease (EHD), and macrovascular invasion (MVI). The primary outcome was overall survival. Survival was assessed by the Kaplan-Meier method. Predictors of death after dropout were assessed by multivariable Cox regression. Results. During the study period, 172 patients dropped out due to HCC progression. Of those, 37 (21.5%), 74 (43%), and 61 (35.5%) dropped out due to LAD, EHD, and MVI, respectively. Median survival according to cause of dropout (LAD, EHD, or MVI) was 1.0, 4.4, or 3.3 months, respectively (P = 0.01). Model for End-stage Liver Disease (MELD) score (hazard ratio [HR], 1.04; 95% confidence interval [CI], 1.01-1.08), alcoholic liver disease (HR, 1.66; 95% CI, 1.02-2.71), and alpha-fetoprotein >1000 ng/mL (HR, 1.86; 95% CI, 1.22-2.84) were predictors of mortality after dropout. Dropout due to EHD (HR, 0.61; 95% CI, 0.38-0.98) and undergoing treatment after dropout were protective factors (HR, 0.32; 95% CI, 0.21-0.48) for death. Conclusions. Patient prognosis after dropout is dismal. However, a subgroup of patients may have longer survival. The present study identifies the patterns of waitlist dropout in patients with HCC and provides evidence for the effectiveness of treatment strategies offered to HCC patients after dropout.
引用
收藏
页码:2136 / 2143
页数:8
相关论文
共 50 条
  • [31] ASSOCIATION OF NEIGHBORHOOD SOCIAL DETERMINANTS WITH WAITLIST DROPOUT FOR LIVER TRANSPLANT CANDIDATES WITH HEPATOCELLULAR CARCINOMA
    Zhou, Kali
    Ha, Nghiem Bao
    Dodge, Jennifer
    Thompson, Laura Katherine
    Cockburn, Myles
    Terrault, Norah
    Mehta, Neil
    HEPATOLOGY, 2021, 74 : 371A - 371A
  • [32] Downstaging Techniques for Hepatocellular Carcinoma in Candidates Awaiting Liver Transplantation
    Matevish, Lauren
    Patel, Madhukar S.
    Vagefi, Parsia A.
    SURGICAL CLINICS OF NORTH AMERICA, 2024, 104 (01) : 145 - 162
  • [33] Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation
    Schlitt, HJ
    Neipp, M
    Weimann, A
    Oldhafer, KJ
    Schmoll, E
    Boeker, K
    Nashan, B
    Kubicka, S
    Maschek, H
    Tusch, G
    Raab, R
    Ringe, B
    Manns, MP
    Pichlmayr, R
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 324 - 331
  • [34] Machine learning to predict waitlist dropout among liver transplant candidates with hepatocellular carcinoma
    Kwong, Allison
    Hameed, Bilal
    Syed, Shareef
    Ho, Ryan
    Mard, Hossein
    Arshad, Sahar
    Ho, Isaac
    Suleman, Tashfeen
    Yao, Francis
    Mehta, Neil
    CANCER MEDICINE, 2022, 11 (06): : 1535 - 1541
  • [35] Higher hepatocellular carcinoma tumor burden score is associated with worse outcomes in patients listed for liver transplantation due to higher waitlist dropout rates
    Liu, Hao
    Kaltenmeier, Christof
    Cruz, Ruy
    Thompson, Ann
    Reddy, Dheera
    Ashwat, Eishan
    D'Alesio, Mark
    Lebowitz, Steven
    Tohme, Samer
    Geller, David
    Tevar, Amit
    Hughes, Christopher
    Humar, Abhinav
    Behari, Jaideep
    Alberola, Ramon Bataller
    Molinari, Michele
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 16 - 17
  • [36] Impact of Multiple Transarterial Chemoembolization Treatments on Hepatocellular Carcinoma for Patients Awaiting Liver Transplantation
    Lai, Quirino
    Lerut, Jan
    LIVER TRANSPLANTATION, 2016, 22 (01) : 136 - 137
  • [37] Hepatocellular carcinoma surveillance in patients awaiting liver transplantation can be cost-effective.
    Saab, S
    Ly, D
    Nieto, J
    Kanwal, F
    Durazo, F
    Han, S
    Busuttil, R
    HEPATOLOGY, 2002, 36 (04) : 717A - 717A
  • [38] Impact of Multiple Transarterial Chemoembolization Treatments on Hepatocellular Carcinoma for Patients Awaiting Liver Transplantation
    Terzi, Eleonora
    Kim, W. Ray
    Sanchez, William
    Charlton, Michael R.
    Schmeltzer, Paul
    Gores, Gregory J.
    Andrews, James C.
    Smyrk, Thomas C.
    Heimbach, Julie K.
    LIVER TRANSPLANTATION, 2015, 21 (02) : 248 - 257
  • [39] Response to Therapy as a Criterion for Awarding Priority to Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation
    Alessandro Vitale
    Francesco D’Amico
    Anna Chiara Frigo
    Francesco Grigoletto
    Alberto Brolese
    Giacomo Zanus
    Daniele Neri
    Amedeo Carraro
    Francesco Enrico D’Amico
    Patrizia Burra
    Francesco Russo
    Paolo Angeli
    Umberto Cillo
    Annals of Surgical Oncology, 2010, 17 : 2290 - 2302
  • [40] Response to Therapy as a Criterion for Awarding Priority to Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation
    Vitale, Alessandro
    D'Amico, Francesco
    Frigo, Anna Chiara
    Grigoletto, Francesco
    Brolese, Alberto
    Zanus, Giacomo
    Neri, Daniele
    Carraro, Amedeo
    D'Amico, Francesco Enrico
    Burra, Patrizia
    Russo, Francesco
    Angeli, Paolo
    Cillo, Umberto
    ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (09) : 2290 - 2302